Acadia Pharmaceuticals | ACAD - Interest Income


Acadia Pharmaceuticals reported $8.06M in Interest Income for its fiscal quarter ending in March of 2026.





Interest Income Change Date
Acadia Pharmaceuticals USD 8.06M 277K Mar/2026
ALKERMES USD 8.54M 3.59M Mar/2026
Alnylam Pharmaceuticals USD 26.6M 32K Mar/2026
Biogen USD 37.9M 700K Mar/2026
BioMarin Pharmaceutical USD 22.56M 3.35M Mar/2026
Cara Therapeutics USD 347K 74K Mar/2025
Corcept Therapeutics USD 4.89M 537K Mar/2026
Cytokinetics USD 11.02M 448K Mar/2026
Eisai JPY 3.11B 783M Mar/2024
Eli Lilly USD 65M 25M Sep/2025
Incyte USD 38.12M 4.43M Jun/2026
J&J USD 2.27 0.13 Jun/2026
Moderna USD 72M 2M Mar/2026
Pfizer USD -0.04 115M Jun/2026
Prothena USD 2.42M 935K Mar/2026
Sarepta Therapeutics USD 7M 1.74M Mar/2026
Ultragenyx Pharmaceutical USD 6M 512K Mar/2026
Vertex Pharmaceuticals USD 120.6M 5.8M Jun/2026